Opthea Key Executives
This section highlights Opthea's key executives, including their titles and compensation details.
Find Contacts at Opthea
(Showing 0 of )
Opthea Earnings
This section highlights Opthea's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Opthea, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Revenue | $124.67K | $161.16K | $125.05K | $91.98K | $145.90K |
| Cost of Revenue | $- | $250.47K | $232.47K | $571.98K | $517.26K |
| Gross Profit | $124.67K | $-89.31K | $-107.42K | $-480.00K | $-371.37K |
| Gross Profit Ratio | 100.00% | -55.42% | -85.91% | -521.85% | -254.54% |
| Research and Development Expenses | $176.33M | $181.56M | $108.46M | $34.71M | $17.48M |
| General and Administrative Expenses | $15.49M | $19.27M | $16.30M | $11.88M | $6.61M |
| Selling and Marketing Expenses | $- | $22.63M | $8.52M | $6.54M | $43.13K |
| Selling General and Administrative Expenses | $15.49M | $41.90M | $24.83M | $18.42M | $6.65M |
| Other Expenses | $152.46K | $12.30M | $- | $- | $- |
| Operating Expenses | $191.97M | $223.46M | $133.29M | $53.13M | $24.71M |
| Cost and Expenses | $191.97M | $223.61M | $133.40M | $53.27M | $25.23M |
| Interest Income | $3.39M | $4.80M | $324.70K | $498.70K | $696.18K |
| Interest Expense | $30.26M | $20.01M | $- | $- | $- |
| Depreciation and Amortization | $103.03K | $150.49K | $108.08K | $143.00K | $144.02K |
| EBITDA | $-200.02M | $-223.30M | $-133.16M | $-52.85M | $-24.92M |
| EBITDA Ratio | -160443.72% | -138554.61% | -106489.56% | -57455.77% | -17079.20% |
| Operating Income | $-191.84M | $-223.45M | $-133.27M | $-53.18M | $-24.70M |
| Operating Income Ratio | -153885.37% | -138647.99% | -106575.99% | -57815.66% | -16929.71% |
| Total Other Income Expenses Net | $-37.81M | $-70.67M | $-3.41M | $-14.23M | $310.76K |
| Income Before Tax | $-229.65M | $-220.69M | $-136.68M | $-67.41M | $-24.39M |
| Income Before Tax Ratio | -184215.67% | -136936.62% | -109300.18% | -73285.73% | -16716.71% |
| Income Tax Expense | $-9.41M | $-8.81M | $-8.69M | $-6.62M | $8.27M |
| Net Income | $-220.24M | $-211.88M | $-127.99M | $-60.79M | $-16.12M |
| Net Income Ratio | -176665.73% | -131469.80% | -102353.69% | -66087.58% | -11047.04% |
| EPS | $-22.16 | $-3.60 | $-2.72 | $-1.44 | $-0.50 |
| EPS Diluted | $-22.16 | $-3.60 | $-2.72 | $-1.44 | $-0.49 |
| Weighted Average Shares Outstanding | 79.78M | 58.69M | 46.62M | 42.49M | 32.56M |
| Weighted Average Shares Outstanding Diluted | 79.78M | 58.69M | 46.62M | 42.49M | 32.60M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 | December 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $89.39K | $93.18K | $83.34K | $77.79K | $66.10K | $124.69K | $-214.06K | $41.47K | $-127.33K | $273.12K | $- | $- | $- | $49.42K | $43.13K | $31.73K | $45.21K | $292.44K | $321.60K | $256.84K |
| Cost of Revenue | $222.91K | $78.38K | $127.93K | $119.89K | $179.10K | $- | $474.41K | $- | $313.20K | $203.98K | $- | $- | $- | $139.82K | $108.22K | $149.25K | $86.42K | $261.99K | $201.81K | $142.94K |
| Gross Profit | $-133.52K | $14.80K | $-44.59K | $-42.10K | $-113.00K | $124.69K | $-688.47K | $41.47K | $-440.52K | $69.13K | $- | $- | $- | $-90.40K | $-65.09K | $-117.51K | $-41.21K | $30.44K | $119.79K | $113.91K |
| Gross Profit Ratio | -149.37% | 15.88% | -53.50% | -54.12% | -170.97% | 100.00% | 321.62% | 100.00% | 345.98% | 25.31% | 0.00% | 0.00% | 0.00% | -182.92% | -150.92% | -370.33% | -91.16% | 10.41% | 37.25% | 44.35% |
| Research and Development Expenses | $139.38M | $129.65M | $89.84M | $91.72M | $67.84M | $43.50M | $16.15M | $18.81M | $9.14M | $8.34M | $14.00M | $17.35M | $14.22M | $10.67M | $2.52M | $3.71M | $3.93M | $1.94M | $3.32M | $3.89M |
| General and Administrative Expenses | $9.81M | $13.28M | $19.73M | $25.49M | $18.19M | $- | $12.73M | $- | $4.19M | $2.42M | $- | $- | $- | $2.57M | $2.37M | $2.23M | $2.47M | $1.48M | $1.86M | $1.42M |
| Selling and Marketing Expenses | $- | $967.92K | $-3.94M | $743.06K | $-3.55M | $- | $-2.12M | $- | $-848.04K | $890.81K | $- | $- | $- | $51.89K | $55.29K | $52.63K | $53.58K | $52.89K | $52.60K | $51.62K |
| Selling General and Administrative Expenses | $9.81M | $14.25M | $15.79M | $26.24M | $14.64M | $10.50M | $10.61M | $7.61M | $3.34M | $3.31M | $3.12M | $2.44M | $2.26M | $2.62M | $2.43M | $2.28M | $2.53M | $1.53M | $1.91M | $1.47M |
| Other Expenses | $138.29M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $287.48M | $143.90M | $105.63M | $117.95M | $84.77M | $53.99M | $26.76M | $26.41M | $13.18M | $11.53M | $17.11M | $19.79M | $16.47M | $13.30M | $4.95M | $5.99M | $6.46M | $3.48M | $5.23M | $5.36M |
| Cost and Expenses | $287.70M | $143.97M | $105.70M | $117.95M | $84.95M | $53.99M | $27.24M | $26.41M | $13.49M | $11.74M | $17.11M | $19.79M | $16.47M | $13.44M | $5.06M | $6.14M | $6.54M | $3.74M | $5.43M | $5.51M |
| Interest Income | $2.79M | $2.76M | $3.14M | $1.65M | $167.34K | $- | $- | $- | $696.18K | $268.73K | $367.35K | $388.42K | $447.00K | $554.51K | $352.16K | $148.00K | $206.15K | $229.82K | $295.26K | $- |
| Interest Expense | $30.03M | $16.09M | $14.78M | $5.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $14.65K | $78.38K | $62.34K | $10.73K | $13.30K | $86.06K | $10.07K | $55.81K | $70.66K | $69.20K | $36.01K | $36.01K | $- | $13.31K | $11.22K | $15.40K | $11.51K | $19.28K | $19.45K | $19.11K |
| EBITDA | $-147.07M | $-138.97M | $-105.55M | $-112.96M | $-82.83M | $-53.87M | $-27.47M | $-26.37M | $-13.11M | $-11.56M | $-16.63M | $-19.79M | $-16.47M | $-13.38M | $-4.66M | $-5.14M | $-4.99M | $-2.73M | $-4.22M | $-4.55M |
| EBITDA Ratio | -164523.40% | -149138.63% | -126656.23% | -145208.05% | -125318.11% | -43201.74% | 12831.92% | -63601.88% | 10297.76% | -4233.39% | - | - | - | -27064.49% | -10794.53% | -16206.69% | -11031.12% | -933.47% | -1311.11% | -1771.91% |
| Operating Income | $-287.61M | $-143.88M | $-105.61M | $-117.88M | $-82.84M | $-53.87M | $-27.45M | $-26.37M | $-13.12M | $-11.58M | $-17.11M | $-19.79M | $-16.47M | $-13.39M | $-5.01M | $-6.11M | $-6.50M | $-3.45M | $-5.11M | $-5.25M |
| Operating Income Ratio | -321751.70% | -154410.43% | -126731.03% | -151525.57% | -125327.78% | -43201.75% | 12824.93% | -63601.88% | 10301.74% | -4239.45% | - | - | - | -27091.42% | -11621.10% | -19260.25% | -14375.18% | -1178.04% | -1588.47% | -2044.01% |
| Total Other Income Expenses Net | $95.07M | $-11.26M | $3.03M | $-281.94K | $-2.13M | $-1.67M | $-1.89M | $-12.13M | $1.95K | $113.37K | $484.80K | $873.66K | $846.68K | $94.06K | $619.36K | $1.14M | $985.81K | $856.67K | $1.28M | $958.17K |
| Income Before Tax | $-192.54M | $-155.14M | $-102.59M | $-118.16M | $-84.71M | $-55.54M | $-29.35M | $-38.51M | $-12.92M | $-11.47M | $-16.63M | $-18.92M | $-15.62M | $-13.29M | $-4.39M | $-4.97M | $-5.51M | $-2.59M | $-3.83M | $-4.29M |
| Income Before Tax Ratio | -215399.52% | -166491.92% | -123100.26% | -151887.99% | -128164.67% | -44541.15% | 13709.79% | -92861.56% | 10146.76% | -4197.94% | - | - | - | -26901.10% | -10185.00% | -15656.82% | -12194.47% | -885.10% | -1190.80% | -1670.95% |
| Income Tax Expense | $-6.65M | $-7.72M | $-5.75M | $-3.05M | $4.90M | $-3.99M | $3.19M | $-3.52M | $4.43M | $3.85M | $-7.00M | $-7.64M | $-10.15M | $-1.86M | $-496.93K | $-2.67M | $-712.58K | $-856.62K | $-1.45M | $1.27M |
| Net Income | $-185.99M | $-147.42M | $-96.84M | $-115.11M | $-79.81M | $-51.55M | $-26.16M | $-34.98M | $-8.49M | $-7.62M | $-9.63M | $-11.28M | $-5.47M | $-11.43M | $-3.90M | $-2.30M | $-4.80M | $-1.71M | $-2.37M | $-2.94M |
| Net Income Ratio | -208063.37% | -158205.35% | -116205.57% | -147963.85% | -120752.11% | -41343.74% | 12219.66% | -84365.64% | 6671.28% | -2790.04% | - | - | - | -23132.21% | -9032.78% | -7239.51% | -10618.17% | -583.84% | -737.45% | -1144.86% |
| EPS | $-2.16 | $-2.00 | $-1.60 | $-1.84 | $-1.84 | $-1.12 | $-0.59 | $-0.88 | $-0.25 | $-0.24 | $-0.29 | $-0.36 | $-0.20 | $-0.46 | $-0.18 | $-0.12 | $-0.26 | $-0.09 | $-0.12 | $-0.37 |
| EPS Diluted | $-2.16 | $-2.00 | $-1.60 | $-1.84 | $-1.84 | $-1.12 | $-0.59 | $-0.88 | $-0.25 | $-0.24 | $-0.29 | $-0.36 | $-0.20 | $-0.46 | $-0.18 | $-0.12 | $-0.26 | $-0.09 | $-0.12 | $-0.37 |
| Weighted Average Shares Outstanding | 85.47M | 74.08M | 61.95M | 61.91M | 44.00M | 46.56M | 44.69M | 39.48M | 33.59M | 31.54M | 33.07M | 31.17M | 26.74M | 25.07M | 21.54M | 18.77M | 18.83M | 18.72M | 19.24M | 8.03M |
| Weighted Average Shares Outstanding Diluted | 85.47M | 74.08M | 61.95M | 61.91M | 44.00M | 46.56M | 44.69M | 39.48M | 33.66M | 31.54M | 33.07M | 31.17M | 26.74M | 25.07M | 21.54M | 18.77M | 18.83M | 18.72M | 19.25M | 8.03M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $172.47M | $133.99M | $64.90M | $157.43M | $62.02M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $172.47M | $133.99M | $64.90M | $157.43M | $62.02M |
| Net Receivables | $11.82M | $6.56M | $- | $- | $8.82M |
| Inventory | $- | $1 | $- | $1 | $- |
| Other Current Assets | $3.90M | $7.25M | $8.72M | $19.58K | $478.63K |
| Total Current Assets | $188.19M | $147.80M | $87.12M | $183.97M | $71.32M |
| Property Plant Equipment Net | $131.95K | $302.69K | $40.84K | $155.99K | $280.69K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $289.98K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $466.70K | $80.42K | $160.39K | $232.49K | $-1 |
| Total Non-Current Assets | $598.65K | $383.12K | $201.23K | $388.48K | $570.67K |
| Other Assets | $- | $1 | $1 | $1 | $1 |
| Total Assets | $188.79M | $148.19M | $87.32M | $184.36M | $71.89M |
| Account Payables | $38.06M | $17.84M | $11.40M | $2.42M | $4.05M |
| Short Term Debt | $93.03K | $97.48K | $- | $112.97K | $99.75K |
| Tax Payables | $44.59K | $73.42K | $63.02K | $111.62K | $56.92K |
| Deferred Revenue | $- | $73.42K | $- | $111.62K | $56.92K |
| Other Current Liabilities | $25.86M | $728.75K | $6.05M | $1.50M | $2.71M |
| Total Current Liabilities | $64.06M | $28.16M | $17.51M | $4.14M | $6.92M |
| Long Term Debt | $141.55M | $84.23K | $- | $- | $82.55K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $58.99M | $128.74M | $40.68K | $22.53K | $77.69K |
| Total Non-Current Liabilities | $200.55M | $128.82M | $40.68K | $22.53K | $160.23K |
| Other Liabilities | $- | $1 | $1 | $- | $- |
| Total Liabilities | $264.60M | $156.98M | $17.55M | $4.16M | $7.08M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $466.08M | $482.06M | $342.15M | $311.88M | $162.10M |
| Retained Earnings | $-579.70M | $-540.02M | $-315.48M | $-165.33M | $-102.59M |
| Accumulated Other Comprehensive Income Loss | $37.81M | $49.16M | $43.11M | $33.65M | $5.29M |
| Other Total Stockholders Equity | $- | $1 | $- | $- | $- |
| Total Stockholders Equity | $-75.81M | $-8.79M | $69.77M | $180.20M | $64.81M |
| Total Equity | $-75.81M | $-8.79M | $69.77M | $180.20M | $64.81M |
| Total Liabilities and Stockholders Equity | $188.79M | $148.19M | $87.32M | $184.36M | $71.89M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $188.79M | $148.19M | $87.32M | $184.36M | $71.89M |
| Total Investments | $- | $- | $- | $- | $289.98K |
| Total Debt | $141.65M | $272.98K | $- | $150.47K | $265.08K |
| Net Debt | $-30.82M | $-133.71M | $-64.90M | $-157.28M | $-61.76M |
Balance Sheet Charts
| Breakdown | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 | December 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $172.47M | $157.07M | $133.99M | $209.06M | $44.63M | $121.41M | $118.19M | $202.54M | $62.02M | $75.09M | $21.53M | $40.14M | $32.51M | $41.94M | $39.93M | $13.14M | $10.82M | $17.76M | $14.14M | $18.99M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $126.28K | $169.10K | $- | $- |
| Cash and Short Term Investments | $172.47M | $157.07M | $133.99M | $209.06M | $44.63M | $121.41M | $118.19M | $202.54M | $62.02M | $75.09M | $21.53M | $40.14M | $32.51M | $41.94M | $39.93M | $13.14M | $10.94M | $17.93M | $14.14M | $18.99M |
| Net Receivables | $11.82M | $748.15K | $9.86M | $13.50M | $- | $665.62K | $- | $4.37M | $8.82M | $4.16M | $14.93M | $8.08M | $12.41M | $- | $- | $- | $- | $- | $- | $796.26K |
| Inventory | $- | $-1.62M | $1 | $2 | $-13.41M | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $-509.14K | $- | $-265.91K | $- | $-616.92K | $- |
| Other Current Assets | $3.90M | $3.47M | $2.63M | $4.08M | $8.72M | $23.85M | $14.39M | $6.08M | $478.63K | $4.43M | $15.36M | $8.30M | $12.70M | $5.20M | $118.31K | $1.93M | $135.94K | $1.19M | $248.43K | $4.01M |
| Total Current Assets | $188.19M | $166.34M | $147.80M | $226.64M | $59.91M | $149.94M | $138.12M | $213.00M | $71.32M | $79.52M | $36.89M | $48.44M | $45.21M | $47.14M | $42.52M | $15.08M | $12.43M | $19.12M | $16.81M | $23.79M |
| Property Plant Equipment Net | $131.95K | $154.60K | $302.69K | $351.49K | $28.08K | $90.31K | $117.11K | $212.36K | $280.69K | $430.67K | $54.06K | $53.04K | $69.09K | $77.82K | $49.05K | $80.68K | $68.07K | $93.04K | $84.53K | $129.38K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $289.98K | $314.84K | $714.12K | $507.79K | $793.30K | $1.07M | $882.36K | $863.97K | $235.91K | $963.80K | $1.57M | $1.77M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $466.70K | $10.56K | $80.42K | $113.94K | $110.30K | $194.26K | $174.54K | $- | $-1 | $- | $- | $- | $-1 | $- | $1 | $- | $- | $- | $- | $35.48K |
| Total Non-Current Assets | $598.65K | $165.17K | $383.12K | $465.43K | $138.38K | $284.58K | $291.65K | $212.36K | $570.67K | $745.50K | $768.18K | $560.83K | $862.39K | $1.15M | $931.42K | $944.65K | $303.98K | $1.06M | $1.65M | $1.93M |
| Other Assets | $- | $- | $1 | $- | $- | $1 | $- | $- | $1 | $- | $- | $- | $1 | $- | $- | $- | $1 | $- | $1 | $- |
| Total Assets | $188.79M | $166.50M | $148.19M | $227.10M | $60.05M | $150.22M | $138.41M | $213.21M | $71.89M | $80.26M | $37.66M | $49.00M | $46.08M | $48.29M | $43.45M | $16.02M | $12.73M | $20.18M | $18.46M | $25.72M |
| Account Payables | $38.06M | $31.70M | $26.81M | $8.67M | $11.40M | $8.31M | $2.42M | $1.94M | $4.05M | $5.66M | $5.90M | $8.76M | $5.31M | $- | $1.20M | $- | $1.18M | $- | $1.31M | $- |
| Short Term Debt | $93.03K | $87.72K | $243.94K | $84.31K | $- | $67.25K | $112.97K | $256.56K | $99.75K | $143.62K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $44.59K | $- | $73.42K | $- | $43.33K | $- | $83.80K | $- | $- | $- | $56.02K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $2 | $73.42K | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $25.86M | $798.48K | $1.03M | $5.13M | $596.20K | $543.85K | $492.00K | $13.32M | $2.77M | $576.82K | $564.14K | $477.69K | $2.56M | $4.72M | $343.48K | $2.15M | $319.74K | $1.10M | $409.37K | $1.94M |
| Total Current Liabilities | $64.06M | $32.59M | $28.16M | $13.89M | $12.04M | $12.27M | $3.11M | $15.52M | $6.92M | $6.38M | $6.52M | $9.24M | $7.86M | $4.72M | $1.54M | $2.15M | $1.50M | $1.10M | $1.72M | $1.94M |
| Long Term Debt | $141.55M | $42.11K | $84.23K | $126.34K | $- | $- | $- | $46.78K | $82.55K | $242.64K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $58.99M | $180.78M | $128.74M | $129.82M | $27.97K | $32.73K | $16.91K | $64.74K | $77.69K | $32.27K | $24.84K | $18.56K | $39.40K | $45.10K | $38.39K | $56.73K | $46.49K | $80.15K | $79.06K | $202.78K |
| Total Non-Current Liabilities | $200.55M | $180.82M | $128.82M | $129.95M | $27.97K | $32.73K | $16.91K | $111.53K | $160.23K | $274.91K | $24.84K | $18.56K | $39.40K | $45.10K | $38.39K | $56.73K | $46.49K | $80.15K | $79.06K | $202.78K |
| Other Liabilities | $- | $- | $1 | $- | $- | $1 | $- | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $264.60M | $213.41M | $156.98M | $143.83M | $12.07M | $12.30M | $3.12M | $15.63M | $7.08M | $6.66M | $6.54M | $9.26M | $7.90M | $4.77M | $1.58M | $2.21M | $1.55M | $1.18M | $1.80M | $2.15M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $12.51M | $- | $- | $- | $- | $- | $- | $0 | $- | $0 | $- | $0 | $- |
| Common Stock | $466.08M | $374.32M | $482.06M | $472.74M | $235.28M | $322.73M | $234.15M | $310.73M | $162.10M | $162.16M | $113.02M | $113.02M | $98.40M | $98.14M | $75.20M | $53.85M | $40.21M | $53.84M | $41.30M | $53.84M |
| Retained Earnings | $-579.70M | $-455.65M | $-540.02M | $-433.59M | $-216.94M | $-222.59M | $-124.12M | $-137.57M | $-102.59M | $-93.68M | $-86.06M | $-76.43M | $-65.15M | $-59.68M | $-37.08M | $-44.35M | $-31.41M | $-30.08M | $-21.76M | $-26.18M |
| Accumulated Other Comprehensive Income Loss | $37.81M | $34.41M | $49.16M | $44.12M | $29.64M | $37.78M | $25.26M | $24.43M | $5.29M | $5.12M | $4.16M | $3.15M | $4.92M | $5.06M | $3.75M | $4.31M | $2.38M | $-4.76M | $-3.50M | $-4.90M |
| Other Total Stockholders Equity | $- | $-190.33M | $1 | $-1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $11.17M | $- | $10.65M | $- | $0 | $- |
| Total Stockholders Equity | $-75.81M | $-46.91M | $-8.79M | $83.27M | $47.98M | $137.92M | $135.29M | $197.59M | $64.81M | $73.61M | $31.12M | $39.74M | $38.17M | $43.52M | $41.87M | $13.81M | $11.19M | $19.00M | $16.03M | $22.76M |
| Total Equity | $-75.81M | $-46.91M | $-8.79M | $83.27M | $47.98M | $137.92M | $135.29M | $197.59M | $64.81M | $73.61M | $31.12M | $39.74M | $38.17M | $43.52M | $41.87M | $13.81M | $11.19M | $19.00M | $16.66M | $23.58M |
| Total Liabilities and Stockholders Equity | $188.79M | $166.50M | $148.19M | $227.10M | $60.05M | $150.22M | $138.41M | $213.21M | $71.89M | $80.26M | $37.66M | $49.00M | $46.08M | $48.29M | $43.45M | $16.02M | $12.73M | $20.18M | $18.46M | $25.72M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $627.10K | $812.30K |
| Total Liabilities and Total Equity | $188.79M | $166.50M | $148.19M | $227.10M | $60.05M | $150.22M | $138.41M | $213.21M | $71.89M | $80.26M | $37.66M | $49.00M | $46.08M | $48.29M | $43.45M | $16.02M | $12.73M | $20.18M | $18.46M | $25.72M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $289.98K | $314.84K | $714.12K | $507.79K | $793.30K | $1.07M | $882.36K | $863.97K | $362.20K | $1.13M | $1.57M | $1.77M |
| Total Debt | $141.65M | $129.84K | $272.98K | $130.05M | $- | $92.50K | $112.97K | $205.89K | $265.08K | $386.26K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-30.82M | $-156.94M | $-133.71M | $-79.01M | $-44.63M | $-121.32M | $-118.08M | $-202.34M | $-61.76M | $-74.70M | $-21.53M | $-40.14M | $-32.51M | $-41.94M | $-39.93M | $-13.14M | $-10.82M | $-17.76M | $-14.14M | $-18.99M |
Annual Cash Flow
| Breakdown | June 30, 2024 | June 30, 2023 | June 30, 2022 | June 30, 2021 | June 30, 2020 |
|---|---|---|---|---|---|
| Net Income | $-220.24M | $-211.88M | $-127.99M | $-60.79M | $-16.12M |
| Depreciation and Amortization | $103.40K | $150.49K | $108.08K | $143.00K | $139.88K |
| Deferred Income Tax | $-9.41M | $-5.93M | $-6.30M | $-4.94M | $-5.71M |
| Stock Based Compensation | $5.08M | $5.83M | $5.25M | $3.90M | $732.69K |
| Change in Working Capital | $17.30M | $20.75M | $20.22M | $-21.60M | $78.14K |
| Accounts Receivables | $-789.84K | $563.29K | $424.19K | $-495.63K | $17.57K |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- |
| Other Working Capital | $18.09M | $20.18M | $19.80M | $-21.11M | $60.57K |
| Other Non Cash Items | $46.15M | $11.77M | $10.34M | $22.23M | $6.59M |
| Net Cash Provided by Operating Activities | $-161.02M | $-179.30M | $-98.37M | $-61.06M | $-8.24M |
| Investments in Property Plant and Equipment | $-33.49K | $-32.64K | $-23.32K | $-17.03K | $-3.67K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $897.10K | $335.75K |
| Other Investing Activities | $- | $- | $- | $892.42K | $486.50K |
| Net Cash Used for Investing Activities | $-33.49K | $-32.64K | $-23.32K | $880.07K | $482.83K |
| Debt Repayment | $-88.68K | $-70.97K | $- | $-87.37K | $-96.77K |
| Common Stock Issued | $158.82M | $81.82M | $354.63K | $105.48M | $49.08M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $85.00M | $166.95M | $-183.03K | $51.37M | $49.08M |
| Net Cash Used Provided by Financing Activities | $243.73M | $248.70M | $236.62K | $156.76M | $48.06M |
| Effect of Forex Changes on Cash | $602.64K | $-2.10M | $-2.38M | $3.50M | $-411.94K |
| Net Change in Cash | $83.28M | $69.08M | $-92.53M | $95.41M | $40.27M |
| Cash at End of Period | $172.47M | $133.99M | $64.90M | $157.43M | $61.80M |
| Cash at Beginning of Period | $89.19M | $64.90M | $157.43M | $62.02M | $21.53M |
| Operating Cash Flow | $-161.02M | $-179.30M | $-98.37M | $-61.06M | $-8.24M |
| Capital Expenditure | $-33.49K | $-32.64K | $-23.32K | $-17.03K | $-3.67K |
| Free Cash Flow | $-161.05M | $-179.34M | $-98.39M | $-61.08M | $-8.25M |
Cash Flow Charts
| Breakdown | June 30, 2024 | December 31, 2023 | June 30, 2023 | December 31, 2022 | June 30, 2022 | December 31, 2021 | June 30, 2021 | December 31, 2020 | June 30, 2020 | December 31, 2019 | June 30, 2019 | December 31, 2018 | June 30, 2018 | December 31, 2017 | June 30, 2017 | December 31, 2016 | June 30, 2016 | December 31, 2015 | June 30, 2015 | December 31, 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-185.99M | $-147.42M | $-96.84M | $-115.11M | $-79.81M | $-51.55M | $-26.16M | $-34.98M | $-8.49M | $-7.62M | $-9.63M | $-11.28M | $-5.47M | $-11.43M | $-3.90M | $-2.30M | $-4.80M | $-1.71M | $-2.37M | $-2.94M |
| Depreciation and Amortization | $51.85K | $78.38K | $62.34K | $72.59K | $13.30K | $- | $49.97K | $- | $70.66K | $69.20K | $- | $- | $- | $- | $26.61K | $- | $30.79K | $- | $38.56K | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $5.09M | $2.48M | $4.48M | $4.19M | $4.07M | $- | $3.07M | $- | $180.94K | $880.37K | $- | $- | $- | $- | $865.86K | $- | $810.93K | $- | $418.29K | $- |
| Change in Working Capital | $-3.30M | $- | $10.00M | $- | $8.91M | $- | $-19.42M | $- | $78.14K | $- | $- | $- | $- | $- | $-213.44K | $- | $30.21K | $- | $204.92K | $- |
| Accounts Receivables | $-1.18M | $- | $568.87K | $- | $445.55K | $- | $-493.05K | $- | $17.57K | $- | $- | $- | $- | $- | $-287.96K | $- | $12.12K | $- | $160.39K | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $-2.11M | $- | $9.43M | $- | $8.47M | $- | $-18.93M | $- | $60.57K | $- | $- | $- | $- | $- | $74.52K | $- | $18.09K | $- | $44.54K | $- |
| Other Non Cash Items | $46.73M | $38.56M | $21.81M | $11.66M | $5.15M | $12.25M | $6.39M | $10.25M | $-3.99M | $10.58M | $-8.99M | $5.71M | $-4.25M | $1.22M | $-1.29M | $760.76K | $767.96K | $1.19M | $740.94K | $-1.12M |
| Net Cash Provided by Operating Activities | $-137.41M | $-106.30M | $-75.09M | $-103.44M | $-61.67M | $-39.31M | $-36.06M | $-24.73M | $-12.16M | $3.91M | $-18.62M | $-5.57M | $-9.72M | $-10.22M | $-4.51M | $-1.54M | $-3.16M | $-521.07K | $-968.90K | $-4.06M |
| Investments in Property Plant and Equipment | $-43.83K | $-6.52K | $-22.02K | $-10.48K | $-22.10K | $-2.26K | $-7.21K | $-2.63K | $493 | $-4.16K | $-18.07K | $- | $-7.62K | $-26.80K | $- | $-3.08K | $-11.72K | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $939.78K | $- | $482.98K | $- | $339.05K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $-2.39K | $- | $3.32K | $482.98K | $- | $- | $- | $- | $- | $171.62K | $- | $-191.47K | $39.19K | $- |
| Net Cash Used for Investing Activities | $-43.83K | $-6.52K | $-22.02K | $-10.48K | $-22.10K | $-2.26K | $-9.60K | $937.15K | $3.81K | $478.82K | $-18.07K | $339.05K | $-7.62K | $-26.80K | $- | $168.54K | $-11.72K | $-191.47K | $39.19K | $- |
| Debt Repayment | $- | $124.64M | $- | $124.06M | $- | $-62.92K | $- | $- | $- | $-66.66K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $212.17M | $-1.95M | $249.68M | $- | $351.55K | $- | $164.89M | $-61.88K | $49.14M | $- | $12.63M | $264.93K | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $-1.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $157.93M | $-124.72M | $2.08M | $125.55M | $-57.74K | $351.98K | $-39.47K | $-13.19M | $-30.07K | $49.14M | $- | $12.63M | $264.93K | $284.72K | $43.40M | $8.42K | $2.16K | $2.05K | $648 | $16.05M |
| Net Cash Used Provided by Financing Activities | $157.93M | $212.09M | $-1.99M | $249.62M | $-57.74K | $289.06K | $-39.47K | $164.83M | $-1.03M | $49.08M | $- | $12.63M | $264.93K | $284.72K | $43.40M | $8.42K | $2.16K | $2.05K | $648 | $16.05M |
| Effect of Forex Changes on Cash | $2.61M | $-9.58M | $2.03M | $-58.52M | $-1.46M | $- | $-14.48M | $- | $-499.76K | $87.78K | $- | $- | $- | $-62.00K | $-77.00K | $17.29K | $-101.64K | $32.63K | $376.28K | $-166.02K |
| Net Change in Cash | $-230.45M | $96.20M | $-75.07M | $87.64M | $-63.21M | $-81.13M | $-202.50M | $140.52M | $-13.07M | $53.55M | $-18.61M | $7.63M | $-9.46M | $41.94M | $-13.14M | $13.14M | $-17.76M | $17.76M | $-18.99M | $18.99M |
| Cash at End of Period | $- | $230.19M | $133.99M | $209.06M | $58.28M | $121.41M | $- | $202.54M | $62.02M | $75.09M | $21.53M | $40.14M | $32.51M | $41.94M | $- | $13.14M | $- | $17.76M | $- | $18.99M |
| Cash at Beginning of Period | $230.45M | $133.99M | $209.06M | $121.41M | $121.49M | $202.54M | $202.50M | $62.02M | $75.09M | $21.53M | $40.14M | $32.51M | $41.97M | $- | $13.14M | $- | $17.76M | $- | $18.99M | $- |
| Operating Cash Flow | $-137.41M | $-106.30M | $-75.09M | $-103.44M | $-61.67M | $-39.31M | $-36.06M | $-24.73M | $-12.16M | $3.91M | $-18.62M | $-5.57M | $-9.72M | $-10.22M | $-4.51M | $-1.54M | $-3.16M | $-521.07K | $-968.90K | $-4.06M |
| Capital Expenditure | $-43.83K | $-6.52K | $-22.02K | $-10.48K | $-22.10K | $-2.26K | $-7.21K | $-2.63K | $493 | $-4.16K | $-18.07K | $- | $-7.62K | $-26.80K | $- | $-3.08K | $-11.72K | $- | $- | $- |
| Free Cash Flow | $-137.45M | $-106.31M | $-75.11M | $-103.45M | $-61.70M | $-39.31M | $-36.07M | $-24.73M | $-12.16M | $3.91M | $-18.63M | $-5.57M | $-9.73M | $-10.24M | $-4.51M | $-1.54M | $-3.17M | $-521.07K | $-968.90K | $-4.06M |
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
$3.41
Stock Price
$524.84M
Market Cap
34
Employees
South Yarra, VIC
Location
Revenue (FY 2024)
$124.67K
-22.6% YoY
Net Income (FY 2024)
$-220.24M
-3.9% YoY
EPS (FY 2024)
$-22.16
-515.6% YoY
Free Cash Flow (FY 2024)
$-161.05M
10.2% YoY
Profitability
Gross Margin
100.0%
Net Margin
-176665.7%
ROE
290.5%
ROA
-116.7%
Valuation
P/E Ratio
-0.67
P/S Ratio
1176.19
EV/EBITDA
-0.58
Market Cap
$524.84M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-161.02M
10.2% YoY
Free Cash Flow
$-161.05M
10.2% YoY
Balance Sheet Summary
Total Assets
$188.79M
27.4% YoY
Total Debt
$141.65M
51789.0% YoY
Shareholder Equity
$-75.81M
-534.3% YoY
Dividend Overview
No Dividend Data
Opthea Limited doesn't currently pay dividends.
Opthea Dividends
Explore Opthea's dividend history, including dividend yield, payout ratio, and historical payments.
Opthea News
Read the latest news about Opthea, including recent articles, headlines, and updates.
Opthea Announces COAST Phase 3 Trial Topline Results
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD.
Opthea Announces Phase 2b Wet AMD Publication
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the publication of sozinibercept Phase 2b data in the peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina.
Opthea to Present at Oppenheimer Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference and host one-one-one meetings.
Opthea Wet AMD Data Featured at Macula Society Meeting
MELBOURNE, Australia, and PRINCETON, N.J., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases.
Opthea to Host Investor Days in New York and Australia
Updates on commercial insights and readiness plans for sozinibercept in wet AMD Opthea management to present in New York City on Tuesday, January 28 at 1:30 PM ET In-person events in Sydney on February 3 and Melbourne on February 5 MELBOURNE, Australia and PRINCETON, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it will host an Investor Day on Tuesday, January 28, 2025 at 1:30 PM ET in New York City, followed by presentations in Sydney and Melbourne in early February.
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Business update to include masked Phase 3 patient demographics and baseline characteristics Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at the 43rd Annual J.P.
Opthea's Wet AMD Program to be Featured at FLORetina 2024
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.
Opthea Appoints Kathy Connell to Board of Directors
Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the “Board”) as a Non-Executive Director.
Opthea Wet AMD Program to be Presented at Innovate Retina
MELBOURNE, Australia, and Princeton, N.J., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be highlighted during the Innovate Retina Meeting on October 17, 2024, in Chicago, Illinois.
Opthea to Participate in the UBS Virtual Ophthalmology Day 2024
MELBOURNE, Australia and PRINCETON, N.J., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in a fireside chat and be available for one-on-one investor meetings at the UBS Virtual Ophthalmology Day 2024 being held on October 2, 2024.
Opthea Announces Completion of Drug Substance PPQ Campaign Validating Manufacturing Process of Sozinibercept
Three consecutive commercial-scale batches successfully produced Major milestone for potential BLA filing of sozinibercept in wet AMD Progress update of drug product PPQ campaign expected in early 2025 MELBOURNE, Australia and PRINCETON, N.J., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the completion of its drug substance Process Performance Qualification (PPQ) campaign for sozinibercept.
Opthea to Have Significant Presence at the 24ᵗʰ EURETINA Congress and EURETINA Innovation Spotlight
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced scientific presentations and a non-CME educational lunch symposium highlighting sozinibercept's potential to become the first therapy in 20 years to improve visual outcomes in wet AMD patients at the European Society of Retina Specialists Annual Conference -- EURETINA Innovation Spotlight (EIS), September 18, 2024, and the 24th EURETINA Congress, September 19-22, 2024, being held at the CCIB in Barcelona, Spain.
Opthea Announces Executive Leadership Changes and Senior Hires
Daniel Geffken appointed Chief Financial Officer ad interim Mike Campbell appointed Chief Commercial Officer Three senior leaders appointed for Biometrics, Clinical Operations and Market Access MELBOURNE, Australia and PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical Company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced executive leadership changes in Commercial and Finance as well as senior hires for Biometrics, Clinical Operations and Market Access.
Opthea to Participate in H.C. Wainwright 26th Global Investment Conference and Cantor 2024 Global Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present and participate in one-on-one investor meetings at the following two investor conferences in September 2024:
Opthea Reports Full-Year Financial Results and Business Updates
Completed patient enrollment in COAST and ShORe pivotal wet AMD trials Financings extended cash runway through topline data readout of both trials in CY2025 Leadership appointments in preparation for regulatory filing and launch of sozinibercept MELBOURNE, Australia, and PRINCETON, N.J., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced financial results for the twelve months ended June 30, 2024, and highlighted recent corporate and clinical updates.
Opthea to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, August 15, 2024
MELBOURNE, Australia and PRINCETON, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference and participate in one-on-one investor meetings on August 15, 2024.
Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board
MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board (“MAB”) composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel.
Opthea A$55.0m (US$36.9m¹) Retail Entitlement Offer Opens
Fully underwritten Retail Entitlement Offer to open at 9:00 am (Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m (US$36.9m 1 ) will close at 5:00 pm (Melbourne time) on 10 July 2024 Prospectus and personalized application forms to be dispatched to eligible retail shareholders MELBOURNE, Australia, and PRINCETON N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the retail component of its 1 for 1.22 pro-rata accelerated non-renounceable entitlement offer (Retail Entitlement Offer) of new fully paid ordinary shares in Opthea (New Shares) and the issue of options to acquire fully paid ordinary shares in Opthea (Options) on a 1 for 3 basis to participants issued New Shares under the Retail Entitlement Offer opens today.
Opthea Successfully Completes Placement and Institutional Component of Entitlement Offer Raising A$171.5 million (US$113.2m¹)
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m (US$36.9m 1 ) will open on 19 June 2024 and close at 5:00 pm (Melbourne time) on 10 July 2024
Opthea To Present at Clinical Trials at the Summit Meeting
MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company will make several presentations at the Clinical Trials at the Summit (CTS) Meeting being held in Park City, Utah on June 8, 2024. Frederic Guerard, PharmD, Chief Executive Officer of Opthea, will participate in a panel, there will be two scientific presentations related to the sozinibercept (OPT-302) clinical trial program and a sponsor talk.
Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025 MELBOURNE, Australia and PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that it has now completed enrollment in both the COAST and ShORe trials constituting its pivotal Phase 3 clinical program.
Opthea Announces Upcoming Presentations at the Retina World Congress 2024
MELBOURNE, Australia and PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that two scientific presentations on the sozinibercept (OPT-302) Phase 2 clinical trial results and ongoing Phase 3 clinical trial program will be made at the Retina World Congress (RWC), being held from May 9-12, 2024 in Fort Lauderdale, Florida. Frederic Guerard, PharmD, Chief Executive Officer (CEO) of Opthea, will participate in the Retina Unplugged panel discussion.
Opthea to Present at the OIS Retina Innovation Summit at ARVO
MELBOURNE, Australia and PRINCETON, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration, today announced that Dr. Frederic Guerard, Chief Executive Officer (CEO) of Opthea, will present the Company's clinical-stage pipeline, as well as its innovation agenda, at the OIS Retina Innovation Summit prior to the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 4, 2024 in Seattle, Washington.
Opthea Appoints John Han, PharmD, as VP Medical Affairs
MELBOURNE, Australia and PRINCETON, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of John Han, PharmD, to the role of Vice President, Medical Affairs, effective April 9, 2024.
Opthea to Participate in the 23ʳᵈ Annual Needham Virtual Healthcare Conference
MELBOURNE, Australia and PRINCETON, N.J., April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference and participate in one-on-one investor meetings on April 11, 2024.
Opthea Appoints Sujal Shah to the Board of Directors
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for OPT.